Objective,Weight,Description,Optimization
Risk Reduction,35%,PRI delta between original and alternative drug,Maximize
Centrality Reduction,20%,Improvement in network centrality position,Maximize
Phenotype Avoidance,25%,Avoiding drugs with harmful interaction phenotypes,Maximize
New Interaction Penalty,20%,Penalty for introducing new severe interactions,Minimize
